Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer

Sang Jin Lee, Yanping Zhang, Sang Don Lee, Chaeyong Jung, Xiong Li, Hong Sup Kim, Kyung Hee Bae, Meei Huey Jeng, Chinghai Kao, Thomas Gardner

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Prostate cancer is the second most commonly diagnosed cancer in men and accounts for significant mortality and morbidity in the United States. Initially androgen-dependent, prostate cancer ultimately becomes androgen-independent, which makes the disease extremely difficult to cure. In this study, we examined the use of conditionally replication-competent adenovirus for the treatment of hormone-independent prostate cancer. We utilized PSME, an enhancer element for prostate-specific PSMA expression, to control viral E1A protein expression and achieve exclusive virus replication in prostate. Western blotting confirmed that PSME mediated high E1A protein expression in PSMA-positive, androgen-independent prostate cancer cells (C4-2 and CWR22rv), but was much less active in PSMA-negative cancer cells (PC-3 and A549). Consistent with E1A protein expression, the recombinant adenovirus Ad5-PSME-E1a replicated in C4-2 and CWR22rv almost as efficiently as wild type with low levels of androgen, but its replication was significantly attenuated in PSMA-negative cells. In the in vitro killing assay, Ad5-PSME-E1a lysed all C4-2 and CWR22rv cells 5 days after infection, with minimal effect on PSMA-negative cells. In addition, injections of 1.7 × 108 plaque-forming units in a CWR22rv xenograft model in nude mice induced significant tumor growth delay, with a substantial necrotic area. These studies suggest that PSME-driven replication-competent adenovirus may be a new therapeutic modality for prostate cancer patients after hormone ablation therapy.

Original languageEnglish
Pages (from-to)1051-1058
Number of pages8
JournalMolecular Therapy
Volume10
Issue number6
DOIs
StatePublished - Dec 2004

Fingerprint

Adenoviridae
Prostatic Neoplasms
Androgens
Prostate
Hormones
Neoplasms
Viral Proteins
Virus Replication
Recombinant Proteins
Heterografts
Nude Mice
Therapeutics
Western Blotting
Morbidity
Injections
Mortality
Growth
Infection
Proteins

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer. / Lee, Sang Jin; Zhang, Yanping; Lee, Sang Don; Jung, Chaeyong; Li, Xiong; Kim, Hong Sup; Bae, Kyung Hee; Jeng, Meei Huey; Kao, Chinghai; Gardner, Thomas.

In: Molecular Therapy, Vol. 10, No. 6, 12.2004, p. 1051-1058.

Research output: Contribution to journalArticle

Lee, SJ, Zhang, Y, Lee, SD, Jung, C, Li, X, Kim, HS, Bae, KH, Jeng, MH, Kao, C & Gardner, T 2004, 'Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer', Molecular Therapy, vol. 10, no. 6, pp. 1051-1058. https://doi.org/10.1016/j.ymthe.2004.08.028
Lee, Sang Jin ; Zhang, Yanping ; Lee, Sang Don ; Jung, Chaeyong ; Li, Xiong ; Kim, Hong Sup ; Bae, Kyung Hee ; Jeng, Meei Huey ; Kao, Chinghai ; Gardner, Thomas. / Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer. In: Molecular Therapy. 2004 ; Vol. 10, No. 6. pp. 1051-1058.
@article{8d8e9ab2eb1c43a493a293b72b3f3afe,
title = "Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer",
abstract = "Prostate cancer is the second most commonly diagnosed cancer in men and accounts for significant mortality and morbidity in the United States. Initially androgen-dependent, prostate cancer ultimately becomes androgen-independent, which makes the disease extremely difficult to cure. In this study, we examined the use of conditionally replication-competent adenovirus for the treatment of hormone-independent prostate cancer. We utilized PSME, an enhancer element for prostate-specific PSMA expression, to control viral E1A protein expression and achieve exclusive virus replication in prostate. Western blotting confirmed that PSME mediated high E1A protein expression in PSMA-positive, androgen-independent prostate cancer cells (C4-2 and CWR22rv), but was much less active in PSMA-negative cancer cells (PC-3 and A549). Consistent with E1A protein expression, the recombinant adenovirus Ad5-PSME-E1a replicated in C4-2 and CWR22rv almost as efficiently as wild type with low levels of androgen, but its replication was significantly attenuated in PSMA-negative cells. In the in vitro killing assay, Ad5-PSME-E1a lysed all C4-2 and CWR22rv cells 5 days after infection, with minimal effect on PSMA-negative cells. In addition, injections of 1.7 × 108 plaque-forming units in a CWR22rv xenograft model in nude mice induced significant tumor growth delay, with a substantial necrotic area. These studies suggest that PSME-driven replication-competent adenovirus may be a new therapeutic modality for prostate cancer patients after hormone ablation therapy.",
author = "Lee, {Sang Jin} and Yanping Zhang and Lee, {Sang Don} and Chaeyong Jung and Xiong Li and Kim, {Hong Sup} and Bae, {Kyung Hee} and Jeng, {Meei Huey} and Chinghai Kao and Thomas Gardner",
year = "2004",
month = "12",
doi = "10.1016/j.ymthe.2004.08.028",
language = "English",
volume = "10",
pages = "1051--1058",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer

AU - Lee, Sang Jin

AU - Zhang, Yanping

AU - Lee, Sang Don

AU - Jung, Chaeyong

AU - Li, Xiong

AU - Kim, Hong Sup

AU - Bae, Kyung Hee

AU - Jeng, Meei Huey

AU - Kao, Chinghai

AU - Gardner, Thomas

PY - 2004/12

Y1 - 2004/12

N2 - Prostate cancer is the second most commonly diagnosed cancer in men and accounts for significant mortality and morbidity in the United States. Initially androgen-dependent, prostate cancer ultimately becomes androgen-independent, which makes the disease extremely difficult to cure. In this study, we examined the use of conditionally replication-competent adenovirus for the treatment of hormone-independent prostate cancer. We utilized PSME, an enhancer element for prostate-specific PSMA expression, to control viral E1A protein expression and achieve exclusive virus replication in prostate. Western blotting confirmed that PSME mediated high E1A protein expression in PSMA-positive, androgen-independent prostate cancer cells (C4-2 and CWR22rv), but was much less active in PSMA-negative cancer cells (PC-3 and A549). Consistent with E1A protein expression, the recombinant adenovirus Ad5-PSME-E1a replicated in C4-2 and CWR22rv almost as efficiently as wild type with low levels of androgen, but its replication was significantly attenuated in PSMA-negative cells. In the in vitro killing assay, Ad5-PSME-E1a lysed all C4-2 and CWR22rv cells 5 days after infection, with minimal effect on PSMA-negative cells. In addition, injections of 1.7 × 108 plaque-forming units in a CWR22rv xenograft model in nude mice induced significant tumor growth delay, with a substantial necrotic area. These studies suggest that PSME-driven replication-competent adenovirus may be a new therapeutic modality for prostate cancer patients after hormone ablation therapy.

AB - Prostate cancer is the second most commonly diagnosed cancer in men and accounts for significant mortality and morbidity in the United States. Initially androgen-dependent, prostate cancer ultimately becomes androgen-independent, which makes the disease extremely difficult to cure. In this study, we examined the use of conditionally replication-competent adenovirus for the treatment of hormone-independent prostate cancer. We utilized PSME, an enhancer element for prostate-specific PSMA expression, to control viral E1A protein expression and achieve exclusive virus replication in prostate. Western blotting confirmed that PSME mediated high E1A protein expression in PSMA-positive, androgen-independent prostate cancer cells (C4-2 and CWR22rv), but was much less active in PSMA-negative cancer cells (PC-3 and A549). Consistent with E1A protein expression, the recombinant adenovirus Ad5-PSME-E1a replicated in C4-2 and CWR22rv almost as efficiently as wild type with low levels of androgen, but its replication was significantly attenuated in PSMA-negative cells. In the in vitro killing assay, Ad5-PSME-E1a lysed all C4-2 and CWR22rv cells 5 days after infection, with minimal effect on PSMA-negative cells. In addition, injections of 1.7 × 108 plaque-forming units in a CWR22rv xenograft model in nude mice induced significant tumor growth delay, with a substantial necrotic area. These studies suggest that PSME-driven replication-competent adenovirus may be a new therapeutic modality for prostate cancer patients after hormone ablation therapy.

UR - http://www.scopus.com/inward/record.url?scp=10344244475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10344244475&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2004.08.028

DO - 10.1016/j.ymthe.2004.08.028

M3 - Article

C2 - 15564137

AN - SCOPUS:10344244475

VL - 10

SP - 1051

EP - 1058

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 6

ER -